Sonnet BioTherapeutics (SONN) 10-K 17 Dec 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Sep. 30, 2024	Dec. 16, 2024	Mar. 28, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	001-35570
Entity Registrant Name	SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Entity Central Index Key	0001106838
Entity Tax Identification Number	20-2932652
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	100 Overlook Center
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	(609)
Local Phone Number	375-2227
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	SONN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 46,150,766.40
Entity Common Stock, Shares Outstanding		3,007,431
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.0001
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	Philadelphia, Pennsylvania

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 149,456	$ 2,274,259
Prepaid expenses and other current assets	1,206,409	1,677,396
Incentive tax receivable	762,078	786,574
Total current assets	2,117,943	4,738,229
Property and equipment, net	20,523	33,366
Operating lease right-of-use asset	123,417	193,689
Deferred offering costs	15,000	49,988
Other assets	494,147	414,206
Total assets	2,771,030	5,429,478
Current liabilities:
Accounts payable	2,183,416	2,201,999
Accrued expenses and other current liabilities	942,489	3,230,922
Current portion of operating lease liability	84,291	73,048
Deferred income		18,626
Total current liabilities	3,210,196	5,524,595
Operating lease liability, net of current portion	46,573	130,863
Total liabilities	3,256,769	5,655,458
Commitments and contingencies (Note 5)
Stockholders’ deficit:
Preferred stock, $0.0001 par value: 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.0001 par value: 125,000,000 shares authorized; 650,284 and 218,786 issued and outstanding at September 30, 2024 and 2023, respectively	65	22
Additional paid-in capital	117,195,181	110,017,751
Accumulated deficit	(117,680,985)	(110,243,753)
Total stockholders’ deficit	(485,739)	(225,980)
Total liabilities and stockholders’ deficit	$ 2,771,030	$ 5,429,478

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	650,284	218,786
Common stock, shares outstanding	650,284	218,786

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Collaboration revenue	$ 18,626	$ 147,805
Operating expenses:
Research and development	5,737,252	11,814,690
General and administrative	6,130,845	7,125,732
Total operating expense	11,868,097	18,940,422
Loss from operations	(11,849,471)	(18,792,617)
Foreign exchange gain (loss)	84,293	(40,077)
Other income	4,327,946
Net loss	$ (7,437,232)	$ (18,832,694)
Per share information:
Net loss per share, basic	$ (11.35)	$ (145.13)
Net loss per share, diluted	$ (11.35)	$ (145.13)
Weighted average shares outstanding, basic	655,240	129,760
Weighted average shares outstanding, diluted	655,240	129,760

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2022	$ 4	$ 88,872,336	$ (91,411,059)	$ (2,538,719)
Balance, shares at Sep. 30, 2022	31,496
Sale of common stock, net of issuance costs	$ 10	20,895,948		20,895,958
Sale of common stock, net of issuance costs, shares	104,159
Net share settlement of warrants	$ 6	(6)
Net share settlement of warrants, shares	64,928
Issuance of common stock on vesting of restricted stock units and restricted stock awards
Issuance of common stock on vesting of restricted stock units and restricted stock awards, shares	954
Exercise of warrants	$ 2	847		849
Exercise of warrants, shares	17,249
Share-based compensation		248,626		248,626
Net loss			(18,832,694)	(18,832,694)
Balance at Sep. 30, 2023	$ 22	110,017,751	(110,243,753)	(225,980)
Balance, shares at Sep. 30, 2023	218,786
Sale of common stock, net of issuance costs	$ 17	3,976,365		3,976,382
Sale of common stock, net of issuance costs, shares	167,987
Net share settlement of warrants	$ 9	(9)
Net share settlement of warrants, shares	94,288
Issuance of common stock on vesting of restricted stock units and restricted stock awards
Issuance of common stock on vesting of restricted stock units and restricted stock awards, shares	976
Share-based compensation		231,190		231,190
Net loss			(7,437,232)	(7,437,232)
Retirement of shares in connection with reverse stock split
Retirement of shares in connection with reverse stock split, shares	(190)
Exercise and modification of warrants, net of issuance costs	$ 17	2,969,884		2,969,901
Exercise and modification of warrants, net of issuance costs, shares	168,437
Balance at Sep. 30, 2024	$ 65	$ 117,195,181	$ (117,680,985)	$ (485,739)
Balance, shares at Sep. 30, 2024	650,284

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (7,437,232)	$ (18,832,694)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	12,000	282,000
Depreciation	12,843	12,845
Amortization of operating lease right-of-use asset	70,272	62,905
Share-based compensation	231,190	248,626
Financing costs related to ChEF Purchase Agreement	370,426
Non-cash financing costs	1,732
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	470,987	(33,653)
Incentive tax receivable	24,496	(69,269)
Other assets	(79,941)	(414,206)
Accounts payable	48,423	(2,631,215)
Accrued expenses and other current liabilities	(2,241,246)	231,953
Deferred income	(18,626)	(147,805)
Operating lease liability	(73,047)	(51,329)
Net cash used in operating activities	(8,607,723)	(21,341,842)
Cash flows from investing activities:
Purchases of in-process research and development	(12,000)	(443,250)
Net cash used in investing activities	(12,000)	(443,250)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	3,896,577	21,006,371
Payment of deferred offering costs	(15,000)
Payment of financing costs related to ChEF Purchase Agreement	(370,426)
Proceeds from exercise of warrants, net of issuance costs	2,983,769	849
Repayments of related party notes		(748)
Net cash provided by financing activities	6,494,920	21,006,472
Net decrease in cash	(2,124,803)	(778,620)
Cash, beginning of year	2,274,259	3,052,879
Cash, end of year	149,456	2,274,259
Supplemental disclosure of non-cash operating, investing and financing activities:
Deferred offering costs charged against proceeds from sale of common stock		32,340
Deferred offering costs in accounts payable and accrued expenses		49,988
Net settlement of warrants	9	52
Common stock and warrant issuance costs in accounts payable and accrued expenses	$ 13,868	$ 78,073

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (7,437,232)	$ (18,832,694)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Description of

Organization and Description of Business	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of business Sonnet BioTherapeutics, Inc. (“Prior Sonnet”) was incorporated as a New Jersey corporation on April 6, 2015. Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (“Chanticleer”) on April 1, 2020. After the merger, Chanticleer changed its name to Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”). Sonnet is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single or bifunctional action. Known as F H ® H H Sonnet’s lead proprietary asset, SON-1010, is a fully human version of Interleukin 12 (“IL-12”), covalently linked to the F H In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (Tecentriq®). The companies have entered into a Master Clinical Trial and Supply Agreement (“MCSA”), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (“PROC”) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and proof-of-concept study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for SB221. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (“MTD”) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (“RP2D”). Part 2 of the study will then investigate SON-1010 in combination with atezolizumab, or the standard of care (“SOC”) for PROC in a randomized comparison to show proof-of-concept (“POC”). As part of the ongoing cost-cutting efforts, all antiviral development with SON-1010 has been suspended. The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 (“IL-6”), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (“CIPN”) and Diabetic Peripheral Neuropathy (“DPN”). Sonnet received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN during the third quarter of 2022. The Data Safety Monitoring Board (“DSMB”) overseeing the study met during the first calendar quarter of 2024 and cleared the trial to proceed to Part 2. Following the completion of the DSMB review, Sonnet announced initial safety data from the CIPN study. Pursuant to a license agreement the Company entered into with New Life Therapeutics Pte, Ltd. (“New Life”) of Singapore in May 2021, Sonnet and New Life would have been jointly responsible for developing SON-080 in DPN. The objective will be to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. SON-1210 (IL12-FHAB-IL15), Sonnet’s lead bifunctional construct, combines F H SON-1411 (IL18-FHAB-IL12) is a bifunctional combination of human Interleukin 18 (“IL-18”), which was modified to resist interaction with the IL-18 inhibitor binding protein, and single-chain human IL-12 for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2023, activities will continue through 2024 with the potential to generate a drug suitable for preclinical studies and subsequent human studies. Sonnet has completed sequence confirmation for SON-3015 (anti-IL6-FHAB-anti-TGFβ). Early-stage bifunctional drug has been generated and is being stored for future use in in vivo mice studies. The Company has elected to place the SON-3015 development program on hold for expense reduction purposes. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements Liquidity The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company’s cash and cash equivalents at September 30, 2024 were $ 0.1 7.7 0.7 0.5 0.4 The Company plans to secure additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry out the Company’s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations. Operations since inception have consisted primarily of organizing the Company, securing financing, developing technologies through research and development and conducting preclinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies a. Basis of presentation The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). b. Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. c. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management’s estimates. d. Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business in one e. Fair value of financial instruments Management believes that the carrying amounts of the Company’s financial instruments, including accounts payable, approximate fair value due to the short-term nature of those instruments. f. Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements g. Impairment of long-lived assets The Company reviews long-lived assets, such as property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the undiscounted future cash flows expected to be generated by that asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. There were no h. Deferred offering costs Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed. As of September 30, 2024, the Company had $ 15,000 49,988 i. Incentive tax receivable Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of both September 30, 2024 and 2023, the Company’s estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $ 0.8 million. In November 2024, the Company received a cash refund of $ 0.7 0.1 0.8 0.8 million for the expected net cash refund related to the tax incentive program was included in research and development expenses. j. Derivative liability The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the ChEF Purchase Agreement (see Note 7) qualified as an embedded derivative. The derivative liability is accounted for separately from the ChEF Purchase Agreement at fair value, which has been deemed de minimus. k. Collaboration revenue Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the “New Life Agreement”) with New Life. See Note 6 for further discussion of the New Life Agreement. l. Research and development expense Research and development expenses include all direct and indirect costs associated with the development of the Company’s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. m. Foreign currency Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the foreign exchange loss line item in the consolidated statements of operations. n. Share-based compensation The Company measures equity classified share-based awards granted to employees and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is the vesting period of the respective award. The Company accounts for forfeitures as they occur. For share-based awards with service-based vesting conditions, the Company recognizes compensation expense on a straight-line basis over the service period. The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. o. Other income The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused net operating losses and unused research and development credits to sell these tax benefits for at least 80% 4.3 Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements p. Income taxes The Company uses the asset-and-liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained. q. Reverse stock split On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split r. Net loss per share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the year ended September 30, 2024 are the pre-funded October 2023 warrants to purchase 99,687 0.0008 187,500 17 0.25 Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares 2024 2023 September 30, 2024 2023 Common stock warrants August 2021 14,031 16,039 Underwriter warrants August 2021 284 284 Chanticleer warrants 6 6 Series C warrants 2,297 4,591 Series 3 warrants 1,566 1,566 Unvested restricted stock units and awards 17,152 288 Common stock warrants February 2023 33,982 33,982 Underwriter warrants February 2023 1,933 5,523 Common stock private placement warrants June 2023 28,409 28,409 Placement agent warrants June 2023 852 852 Common stock warrants October 2023 354,994 — Underwriter warrants October 2023 10,664 — Placement agent warrants June 2024 14,142 — Common stock warrants June 2024 703,125 — Total anti-dilutive weighted average shares 1,183,437 91,540 s. Recent accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	3. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following : Schedule of Accrued Expenses and Other Current Liabilities 2024 2023 September 30, 2024 2023 Compensation and benefits $ 149,802 $ 2,091,196 Research and development 617,545 913,145 Professional fees 173,319 224,031 Other 1,823 2,550 Accrued expenses and other current liabilities $ 942,489 $ 3,230,922 During the first quarter of 2024, the Company cancelled accrued but unpaid bonuses that had been awarded for fiscal years 2022 and 2023, which has been accounted for as a change in estimate. The cancellation of bonuses reduced research and development expenses by $ 1.0 0.9

Leases

Leases	12 Months Ended
	Sep. 30, 2024
Leases
Leases	4. Leases In December 2019, the Company entered into a 36 0.2 The components of lease expense for the years ended September 30, 2024 and 2023 are as follows: Schedule of Lease Expenses Lease expense 2024 2023 Operating lease expense $ 90,837 $ 90,837 Variable lease expense 1,472 5,978 Total lease cost $ 92,309 $ 96,815 At September 30, 2024, the weighted average remaining lease term was 1.6 12% Cash flow information related to operating leases for the years ended September 30, 2024 and 2023 is as follows: Schedule of Operating Lease Liabilities Cash paid for amounts included in the measurement of lease liabilities: 2024 2023 Operating cash flows from operating leases $ 93,614 $ 79,259 Future minimum lease payments under non-cancellable leases at September 30, 2024 are as follows: Schedule of Future Minimum Lease Payments Fiscal year 2025 $ 95,487 2026 48,216 Total undiscounted lease payments 143,703 Less: imputed interest (12,839 ) Total lease liabilities $ 130,864 Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Legal proceedings From time to time, the Company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows. License agreements In July 2012, the Company entered into a Discovery Collaboration Agreement (the “Collaboration Agreement”) with XOMA (US) LLC (“XOMA”), pursuant to which XOMA granted to the Company a non-exclusive, non-transferable license and/or right to use certain materials, technologies and related information related to discovery, optimization and development of antibodies and related proteins and to develop and commercialize products thereunder. The Company is obligated to make contingent milestone payments to XOMA totaling $ 3.8 0.5 No In August 2015, the Company entered into a License Agreement (the “ARES License Agreement”) with Ares Trading, a wholly-owned subsidiary of Merck KGaA (“ARES”). Under the terms of the ARES License Agreement, ARES has granted the Company a sublicensable, exclusive, worldwide, royalty-bearing license on proprietary patents to research, develop, use and commercialize products using atexakin alfa (“Atexakin”), a low dose formulation of human IL-6 in peripheral neuropathies and vascular complications. Pursuant to the ARES License Agreement, the Company will pay ARES high single-digit royalties on net sales of products sold by the Company. Royalties are payable on a product-by-product and country-by-country basis until the later of (i) a specified period of time after the first commercial sale in such country, and (ii) the last date on which such product is covered by a valid claim in such country. In January 2019, the Company entered into a Frame Services and License Agreement (the “Cellca Agreement”) with Sartorius Stedim Cellca GMBH (“Cellca”), pursuant to which Cellca has granted the Company a worldwide, non-exclusive, perpetual, non-transferable license to develop, manufacture or have manufactured, use, sell, import, export and/or otherwise commercialize product based on Cellca’s work to generate a specified transfected cell line and develop an upstream production process for such cell line. The Cellca Agreement is effective unless terminated by either party by giving six months notice, or by giving 14 days notice if terminated for good cause. The Company is obligated to make milestone payments to Cellca totaling up to $ 0.7 0.1 0.6 0.6 0.1 No Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements In October 2021, the Company entered into a Non-Exclusive License Agreement (the “Brink Agreement”) with Brink Biologics Inc. (“Brink”), pursuant to which Brink has granted the Company a non-exclusive, non-transferable license and limited right to sublicense certain materials and related information to develop cell-based assays for batch, quality control, stability, efficacy, potency or any other type of assay required for production and commercialization of products. During the product development phase, the Company was obligated to make annual product development license fee payments of approximately $ 0.1 12,000 0.1 0.1 12,000 In February 2022, the Company entered into a Biological Materials License Agreement (the “InvivoGen Agreement”) with InvivoGen SAS (“InvivoGen”), pursuant to which InvivoGen has granted the Company a worldwide, non-exclusive license to use certain reporter cells for research, development and/or quality control purposes. The InvivoGen Agreement has an initial term of three years and may be extended for two additional three-year periods upon written notice by the Company and payment of an approximately € 0.1 0.1 No In March 2022, the Company entered into a Material Transfer and License Agreement (the “ProteoNic Agreement”) with ProteoNic B.V. (“ProteoNic”), pursuant to which ProteoNic has granted to the Company a non-exclusive, non-transferable, non-sublicensable (except as provided for in the ProteoNic Agreement) license for certain materials, including plasmids and DNA sequences used to generate the vectors used in the Company’s cell lines, for the Company’s use in research, development and commercialization of product. The Company incurred a $ 24,600 No Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements Collaboration Agreement In August 2024, the Company entered into a Master Clinical Collaboration Agreement (the “SOC Agreement”) with the Sarcoma Oncology Center (“SOC”) to advance the development of SON-1210. An Innovative Immuno Oncology Center funded by the SOC will conduct an investigator-initiated Phase 1/2a study of SON-1210 in pancreatic cancer. The Company will provide the study drug and provide support services for the study. If the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur to the SOC a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third-party partnership. Research and development agreement In December 2021, the Company entered into a Research and Development Agreement (the “Navigo Agreement”) with Navigo Proteins GmbH (“Navigo”), pursuant to which Navigo will perform specified evaluation and development procedures to evaluate certain materials to determine their commercial potential. Under the terms of the Navigo Agreement, the Company has granted Navigo a royalty-free, non-exclusive, worldwide, non-sublicensable, non-transferable right and license to use certain technology to perform the evaluation and development activities, and Navigo has granted the Company (i) an exclusive, worldwide, perpetual, irrevocable, sublicensable, transferable, royalty-free right and license to research, develop, use, sell, have sold, distribute, import or otherwise commercially exploit certain materials, and (ii) a non-exclusive, worldwide, perpetual, sublicensable, non-transferable right and license to make or have made such materials. The Company incurred a $ 0.1 1.0 0.3 No no Employment agreements The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined in the contract. In addition, in the event of termination of employment following a change in control, as defined, either by the Company without cause or by the employee for good reason, any unvested portion of the employee’s initial stock option grant becomes immediately vested.

Collaboration Revenue

Collaboration Revenue	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration Revenue	6. Collaboration Revenue Under the New Life Agreement, the Company granted New Life an exclusive license (with the right to sublicense) to develop and commercialize pharmaceutical preparations containing a specific recombinant human IL-6, SON-080 (the “Compound”) (such preparations, the “Products”) for the prevention, treatment or palliation of diabetic peripheral neuropathy (“DPN”) in humans (the “DPN Field”) in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the “Exclusive Territory”). New Life had the option to expand (1) the field of the exclusive license to include the prevention, treatment or palliation of chemotherapy-induced peripheral neuropathy in humans (the “CIPN Field”), which option was non-exclusive and expired on December 31, 2021; and/or (2) the territorial scope of the license to include the People’s Republic of China, Hong Kong and/or India, which option was exclusive and expired on December 31, 2021. The Company will retain all rights to manufacture Compounds and Products anywhere in the world. The Company and New Life shall enter into a follow-on supply agreement pursuant to which the Company shall supply to New Life Products for development and commercialization thereof in the DPN Field in the Exclusive Territory on terms to be negotiated by the parties. The Company will also assist in transferring certain preclinical and clinical development know-how that is instrumental in New Life’s ability to benefit from the license. New Life will bear the cost of, and be responsible for, among other things, conducting clinical studies and additional non-clinical studies and other developmental and regulatory activities for and commercializing Products in the DPN Field in the Exclusive Territory. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements New Life paid the Company a $ 0.5 0.5 New Life is also obligated to pay a non-refundable deferred license fee of an additional $ 1.0 19.0 12 30 The New Life Agreement will remain in effect on a Product-by-Product, country-by-country basis and will expire upon the expiration of the Royalty Term for the last-to-expire Product in the last-to-expire country, subject to (i) each party’s early termination rights including for material breach or insolvency or bankruptcy of the other party and (ii) the Company’s Buy Back Option and New Life’s Give Back Option (as defined below). In addition, New Life granted to the Company an exclusive option to buy back the rights granted by the Company to New Life (the “Buy Back Option”) and the Company granted New Life the right to give back the rights with respect to Products in the DPN Field in one or more countries in the Exclusive Territory on terms to be agreed upon (the “Give Back Option”), which options will expire upon the initiation of a Phase III Trial for the applicable Product. On December 2, 2024, New Life provided the Company with written notice of its intention to exercise its Give Back Option pursuant to the New Life Agreement. The Company is negotiating the terms of the Give Back Option with New Life. If the Company and New Life are unable to reach a mutual agreement on such terms, the Give Back Option will expire unexercised, New Life will retain the rights granted subject to the terms and conditions of the New Life Agreement and the New Life Agreement will remain in effect unless otherwise terminated by either the Company or New Life pursuant to the terms and conditions of the New Life Agreement. Revenue recognition The Company first assessed the New Life Agreement under ASC 808, Collaborative Arrangements Revenue from Contracts with Customers The Company determined the initial transaction price of the single performance obligation to be $ 1.0 Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements Collaboration revenue from the single performance obligation is being recognized over the estimated performance of the R&D services. The Company recognized $ 18,626 0.1 Subsequent to September 30, 2024, New Life informed the Company that it will exercise its Give Back Option under the New Life Agreement. The Company and New Life are currently negotiating the terms under which New Life will give back its license rights.

Stockholders_ Deficit

Stockholders’ Deficit	12 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Deficit	7. Stockholders’ Deficit 2024 events On May 2, 2024, the Company entered into a ChEF Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”), each with Chardan Capital Markets LLC (“Chardan”) related to a “ChEF,” Chardan’s committed equity facility (the “Facility”). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $ 25.0 77,771 19.99 25.0 4 4,706 0.1 0.4 On October 26, 2023, the Company closed a public offering of common stock and certain warrants through Chardan Capital Markets, LLC and Ladenburg Thalmann & Co. Inc. as underwriters, for net proceeds of $ 3.9 163,281 192,187 710,931 12.80 12.7992 12.80 five years 9.60 0.0001 10,664 16.00 five years Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements 2023 events The Company entered into an At-the-Market Sales Agreement with BTIG, LLC (“BTIG”) on August 15, 2022 (the “2022 Sales Agreement”). Pursuant to the 2022 Sales Agreement, the Company could offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $ 25.0 7.8 September 30 17,087 5.7 5.5 On February 10, 2023, the Company closed a public offering of common stock and certain warrants through Chardan Capital Markets, LLC and EF Hutton, division of Benchmark Investments LLC as underwriters, for gross proceeds of $ 15.0 13.6 66,277 12,636 157,818 190.08 190.0624 The common stock warrants are immediately exercisable at a price of $ 190.08 five years 0.02 In addition, warrants to purchase 5,523 237.60 five years On June 30, 2023, the Company closed a registered direct offering of common stock (and common stock equivalents in lieu thereof) and a concurrent private placement of certain common stock warrants through Chardan Capital Markets, LLC as placement agent, for gross proceeds of $ 2.3 1.9 20,795 7,613 28,409 79.20 The common stock warrants were exercisable beginning December 30, 2023 at a price of $ 118.78 12.40 0.02 In addition, warrants to purchase 852 118.78 Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements Common stock warrants As of September 30, 2024, the following equity-classified warrants and related terms were outstanding: Schedule of Warrants Outstanding Warrants Outstanding Exercise Price Expiration Date Common stock warrants August 2021 14,031 $ 2,094.40 August 24, 2026 Underwriter warrants August 2021 284 $ 2,618 August 19, 2026 Chanticleer warrants 6 $ 144,144.00 224,224.00 April 30, 2027 December 17, 2028 Series C warrants 2,297 $ 7,860.16 October 16, 2025 Series 3 warrants 1,566 $ 717.024 August 15, 2027 Common stock warrants February 2023 33,982 $ 190.08 February 10, 2028 Underwriter warrants February 2023 1,933 $ 237.60 February 8, 2028 Common stock private placement warrants June 2023 28,409 $ 12.4000 June 21, 2029 Placement agent warrants June 2023 852 $ 118.7824 December 30, 2026 Common stock warrants October 2023 354,994 $ 9.6000 October 27, 2028 Pre-funded warrants October 2023 99,687 $ 0.0008 — Underwriter warrants October 2023 10,664 $ 16.0000 October 24, 2028 Placement agent warrants June 2024 14,142 $ 14.8800 June 19, 2029 Common stock warrants June 2024 703,125 $ 12.4000 June 21, 2029 Total 1,265,972 On June 19, 2024, the Company entered into inducement offer letter agreements with holders of certain existing warrants issued in October 2023 having an original exercise price of $ 12.80 per share to purchase up to an aggregate of 353,562 shares of the Company’s common stock at a reduced exercise price of $ 9.60 per share. The transaction closed on June 21, 2024, resulting in net proceeds of the Company of $ 2.9 million. Due to beneficial ownership limitations, 187,500 shares of common stock related to the exercise of warrants in this transaction are being held in abeyance as of September 30, 2024. Also in connection with this inducement offer, the Company (i) issued to holders who participated in the transaction new common stock warrants to purchase an aggregate of 703,125 shares of common stock, (ii) reduced the exercise price of existing warrants to purchase 354.994 shares of common stock for those holders who did not exercise warrants in the transaction from $ 12.80 per share to $ 9.60 per share for the remaining term of the warrants, and (iii) reduced the exercise price of certain existing warrants issued in June 2023 to purchase 28,409 shares of common stock from $ 118.78 per share to $ 12.40 per share and extended the expiration date of these warrants from December 30, 2026 to June 21, 2029 . The new common stock warrants are immediately exercisable at a price of $ 12.40 per share and expire five years from the date of issuance. Warrants to purchase 14,142 shares of common stock were issued to the placement agent as compensation for its services related to the offering. These common stock warrants are immediately exercisable at a price of $ 14.88 per share and expire five years from the date of issuance. The incremental fair value associated with the modification of certain existing June and October 2023 warrants to purchase common stock has been accounted for in additional paid-in capital as an equity cost because the modification was done in order to raise equity by inducing the exercise of warrants. During the year ended September 30, 2024, an aggregate of 96,090 94,288 355,937 187,500 3.0 4,302 During the year ended September 30, 2023, 126,583 64,928 During the year ended September 30, 2023, 17,249 During the year ended September 30, 2023, 33

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	8. Share-Based Compensation In April 2020, the Company adopted the 2020 Omnibus Equity Incentive Plan (the “Plan”). On January 1, 2024, the total number of shares authorized under the Plan increased t 17,157 5 able for issuance under the Plan as of September 30, 2024. Th Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements Restricted stock units and awards On January 1, 2024, 9,175 7,977 100 In March of 2021, an additional 19 In December of 2021, 259 In December of 2022, 976 In January 2023, 688 38,837 Any unvested RSUs or RSAs will be forfeited upon termination of services. The fair value of an RSU or RSA is equal to the fair market value of the Company’s common stock on the date of grant. RSU and RSA expense is amortized straight-line over the vesting period. The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying consolidated statements of operations as follows: Schedule of Share-based Compensation Expense 2024 2023 Years ended September 30, 2024 2023 Research and development $ 109,356 $ 121,265 General and administrative 121,834 127,361 Share-based compensation $ 231,190 $ 248,626 The following table summarizes RSU activity under the Plan: Schedule of Restricted Stock Units Activity Weighted Average Grant RSU Date Fair Value Unvested balance at October 1, 2022 266 $ 1,507.76 Granted 976 $ 171.77 Vested (266 ) $ 1,507.76 Forfeited (688 ) $ 170.72 Unvested balance at September 30, 2023 288 $ 174.26 Granted 9,175 $ 14.08 Vested (288 ) $ 174.26 Forfeited — $ — Unvested balance at September 30, 2024 9,175 $ 14.08 As of September 30, 2024, total unrecognized compensation expense relating to unvested RSUs granted was $ 32,314 a weighted-average period o three months The following table summarizes RSA activity under the Plan: Schedule of Restricted Stock Awards Activity Weighted Average Grant RSA Date Fair Value Unvested balance at October 1, 2022 — $ — Granted 688 $ 226.16 Unvested balance at September 30, 2023 688 $ 226.16 Granted 7,977 $ 14.08 Vested (688 ) $ 226.16 Unvested balance at September 30, 2024 7,977 $ 14.08 As of September 30, 2024, total unrecognized compensation expense relating to unvested RSAs granted was $ 28,080 a weighted-average period of three months Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes As of September 30, 2024, the Company had $ 107.5 24.4 16.0 2.6 0.5 0.6 5.8 Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s net operating loss carryforwards may be subject to annual limitations, against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carryforwards are subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax assets with an offsetting reduction in the valuation allowance. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely-than-not be realized. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes interest and penalties accrued on any unrecognized tax benefits within the provision for income taxes in its consolidated statements of operations. No unrecognized tax benefits have been recorded. The tax effects of the temporary differences that gave rise to deferred taxes were as follows: Schedule of Deferred Tax Assets and Liabilities 2024 2023 September 30, 2024 2023 Deferred tax assets: Net operating loss carryforwards $ 26,754,767 $ 27,996,751 Research and development credit carryforwards 3,129,222 3,106,675 Amortization 5,791,883 4,692,227 Share-based compensation 19,357 226 Operating lease liability 36,786 57,319 Accrued expenses and other 26,977 546,612 Section 163(j) disallowed interest expense 761,450 763,172 Gross deferred tax assets 36,520,442 37,162,982 Less: valuation allowance (36,480,967 ) (37,100,582 ) Deferred tax assets 39,475 62,400 Deferred tax liabilities: Property and equipment (4,782 ) (7,954 ) Operating lease right-of-use asset (34,693 ) (54,446 ) Net deferred tax assets $ — $ — Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements During the year ended September 30, 2024, the Company sold New Jersey state net operating losses in the amount of $ 49.4 0.3 4.4 no The Company recorded no income tax expense or benefit for the years ended September 30, 2024 and 2023. A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows: Schedule of Effective Income Tax Rate Reconciliation 2024 2023 Years ended September 30, 2024 2023 U.S. federal statutory rate (21.0 ) % (21.0 )% State taxes, net of federal benefit (5.8 ) (7.1 ) Change in valuation allowance (8.3 ) 30.8 Research and development credit (4.6 ) (5.1 ) Permanent differences 2.7 (1.6 ) Foreign tax rate differential 0.1 0.3 State net operating losses — 3.7 Sale of state net operating losses and research and development credits 51.5 — Other (14.6 ) — Effective income tax rate — % — % In August 2022, the U.S. enacted the Inflation Reduction Act of 2022 (“IRA”). The IRA contains a number of tax-related provisions that will be effective for tax years beginning after December 31, 2022, including a corporate alternative minimum tax of 15 1

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through December 17, 2024, the date at which the consolidated financial statements were available to be issued. On October 8, 2024, the Company entered into a License Agreement (the “Alkem Agreement”) with Alkem Laboratories Limited (“Alkem”) to develop and commercialize SON-080 for DPN in India. Under the terms of the Alkem Agreement, Alkem will pay Sonnet $ 1.0 million in upfront payments and up to an additional $ 1.0 million in milestone payments. Additionally, the Company is entitled to receive a royalty equal to a percentage in the low double digits of the net sales of the product upon commercialization of SON-080 in India, less certain expenses as set forth in the Alkem Agreement. Alkem will conduct all clinical trials that it believes appropriate to obtain regulatory approval in India for SON-080 for the treatment of DPN. Upon payment of a clinical data access fee for Phase 2 and Phase 3 clinical trials, Sonnet will be able to use this data for partnering in any geography outside of India. In October 2024, the Company received $ 0.5 million as an upfront payment related to the Alkem Agreement, which after tax withholdings resulted in a net payment of $ 0.4 million. 155,000 shares of its common stock, (ii) pre-funded warrants to purchase up to 956,111 shares of common stock , and (iii) accompanying warrants to purchase up to 2,222,222 shares of common stock, at the combined public offering price of $ 4.50 per share and accompanying warrant and $ 4.4999 per pre-funded warrant and accompanying common warrant, in each case less underwriting discounts and commissions. The Company raised net proceeds of approximately $ 4.2 million from the underwritten public offering. On December 9, 2024, the Company entered into a definitive agreement with institutional investors for the sale of 1,085,325 1,085,325 2.23 2.10 five years 673,000 673,000 2.23 2.10 3.5

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of presentation	a. Basis of presentation The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).
Consolidation	b. Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates	c. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management’s estimates.
Segment information	d. Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business in one
Fair value of financial instruments	e. Fair value of financial instruments Management believes that the carrying amounts of the Company’s financial instruments, including accounts payable, approximate fair value due to the short-term nature of those instruments.
Property and equipment	f. Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations.
Impairment of long-lived assets	g. Impairment of long-lived assets The Company reviews long-lived assets, such as property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the undiscounted future cash flows expected to be generated by that asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. There were no
Deferred offering costs	h. Deferred offering costs Legal and other costs incurred in relation to equity offerings are capitalized as deferred offering costs and charged against the proceeds from equity offerings when received. If a financing is abandoned, deferred offering costs are expensed. As of September 30, 2024, the Company had $ 15,000 49,988
Incentive tax receivable	i. Incentive tax receivable Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company estimates the amount of cash refund it expects to receive related to the Australian research and development tax incentive program and records the incentive when it is probable (i) the Company will comply with relevant conditions of the program and (ii) the incentive will be received. As of both September 30, 2024 and 2023, the Company’s estimate of the amount of cash refund it expects to receive for eligible spending related to the Australian research and development tax incentive program was $ 0.8 million. In November 2024, the Company received a cash refund of $ 0.7 0.1 0.8 0.8 million for the expected net cash refund related to the tax incentive program was included in research and development expenses.
Derivative liability	j. Derivative liability The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the consolidated statement of operations. The Company determined that certain features under the ChEF Purchase Agreement (see Note 7) qualified as an embedded derivative. The derivative liability is accounted for separately from the ChEF Purchase Agreement at fair value, which has been deemed de minimus.
Collaboration revenue	k. Collaboration revenue Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the “New Life Agreement”) with New Life. See Note 6 for further discussion of the New Life Agreement.
Research and development expense	l. Research and development expense Research and development expenses include all direct and indirect costs associated with the development of the Company’s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies.
Foreign currency	m. Foreign currency Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the U.S. dollar are included in operations in the period in which the transaction occurs and reported within the foreign exchange loss line item in the consolidated statements of operations.
Share-based compensation	n. Share-based compensation The Company measures equity classified share-based awards granted to employees and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is the vesting period of the respective award. The Company accounts for forfeitures as they occur. For share-based awards with service-based vesting conditions, the Company recognizes compensation expense on a straight-line basis over the service period. The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Other income	o. Other income The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused net operating losses and unused research and development credits to sell these tax benefits for at least 80% 4.3
Income taxes	p. Income taxes The Company uses the asset-and-liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained.
Reverse stock split	q. Reverse stock split On September 30, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-8 reverse stock split
Net loss per share	r. Net loss per share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the year ended September 30, 2024 are the pre-funded October 2023 warrants to purchase 99,687 0.0008 187,500 17 0.25 Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Sonnet BioTherapeutics Holdings, Inc. Notes to Consolidated Financial Statements The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares 2024 2023 September 30, 2024 2023 Common stock warrants August 2021 14,031 16,039 Underwriter warrants August 2021 284 284 Chanticleer warrants 6 6 Series C warrants 2,297 4,591 Series 3 warrants 1,566 1,566 Unvested restricted stock units and awards 17,152 288 Common stock warrants February 2023 33,982 33,982 Underwriter warrants February 2023 1,933 5,523 Common stock private placement warrants June 2023 28,409 28,409 Placement agent warrants June 2023 852 852 Common stock warrants October 2023 354,994 — Underwriter warrants October 2023 10,664 — Placement agent warrants June 2024 14,142 — Common stock warrants June 2024 703,125 — Total anti-dilutive weighted average shares 1,183,437 91,540
Recent accounting pronouncements	s. Recent accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares	The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares 2024 2023 September 30, 2024 2023 Common stock warrants August 2021 14,031 16,039 Underwriter warrants August 2021 284 284 Chanticleer warrants 6 6 Series C warrants 2,297 4,591 Series 3 warrants 1,566 1,566 Unvested restricted stock units and awards 17,152 288 Common stock warrants February 2023 33,982 33,982 Underwriter warrants February 2023 1,933 5,523 Common stock private placement warrants June 2023 28,409 28,409 Placement agent warrants June 2023 852 852 Common stock warrants October 2023 354,994 — Underwriter warrants October 2023 10,664 — Placement agent warrants June 2024 14,142 — Common stock warrants June 2024 703,125 — Total anti-dilutive weighted average shares 1,183,437 91,540

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following : Schedule of Accrued Expenses and Other Current Liabilities 2024 2023 September 30, 2024 2023 Compensation and benefits $ 149,802 $ 2,091,196 Research and development 617,545 913,145 Professional fees 173,319 224,031 Other 1,823 2,550 Accrued expenses and other current liabilities $ 942,489 $ 3,230,922

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2024
Leases
Schedule of Lease Expenses	The components of lease expense for the years ended September 30, 2024 and 2023 are as follows: Schedule of Lease Expenses Lease expense 2024 2023 Operating lease expense $ 90,837 $ 90,837 Variable lease expense 1,472 5,978 Total lease cost $ 92,309 $ 96,815
Schedule of Operating Lease Liabilities	Cash flow information related to operating leases for the years ended September 30, 2024 and 2023 is as follows: Schedule of Operating Lease Liabilities Cash paid for amounts included in the measurement of lease liabilities: 2024 2023 Operating cash flows from operating leases $ 93,614 $ 79,259
Schedule of Future Minimum Lease Payments	Future minimum lease payments under non-cancellable leases at September 30, 2024 are as follows: Schedule of Future Minimum Lease Payments Fiscal year 2025 $ 95,487 2026 48,216 Total undiscounted lease payments 143,703 Less: imputed interest (12,839 ) Total lease liabilities $ 130,864

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	12 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Warrants Outstanding	As of September 30, 2024, the following equity-classified warrants and related terms were outstanding: Schedule of Warrants Outstanding Warrants Outstanding Exercise Price Expiration Date Common stock warrants August 2021 14,031 $ 2,094.40 August 24, 2026 Underwriter warrants August 2021 284 $ 2,618 August 19, 2026 Chanticleer warrants 6 $ 144,144.00 224,224.00 April 30, 2027 December 17, 2028 Series C warrants 2,297 $ 7,860.16 October 16, 2025 Series 3 warrants 1,566 $ 717.024 August 15, 2027 Common stock warrants February 2023 33,982 $ 190.08 February 10, 2028 Underwriter warrants February 2023 1,933 $ 237.60 February 8, 2028 Common stock private placement warrants June 2023 28,409 $ 12.4000 June 21, 2029 Placement agent warrants June 2023 852 $ 118.7824 December 30, 2026 Common stock warrants October 2023 354,994 $ 9.6000 October 27, 2028 Pre-funded warrants October 2023 99,687 $ 0.0008 — Underwriter warrants October 2023 10,664 $ 16.0000 October 24, 2028 Placement agent warrants June 2024 14,142 $ 14.8800 June 19, 2029 Common stock warrants June 2024 703,125 $ 12.4000 June 21, 2029 Total 1,265,972

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense	The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying consolidated statements of operations as follows: Schedule of Share-based Compensation Expense 2024 2023 Years ended September 30, 2024 2023 Research and development $ 109,356 $ 121,265 General and administrative 121,834 127,361 Share-based compensation $ 231,190 $ 248,626
Schedule of Restricted Stock Units Activity	The following table summarizes RSU activity under the Plan: Schedule of Restricted Stock Units Activity Weighted Average Grant RSU Date Fair Value Unvested balance at October 1, 2022 266 $ 1,507.76 Granted 976 $ 171.77 Vested (266 ) $ 1,507.76 Forfeited (688 ) $ 170.72 Unvested balance at September 30, 2023 288 $ 174.26 Granted 9,175 $ 14.08 Vested (288 ) $ 174.26 Forfeited — $ — Unvested balance at September 30, 2024 9,175 $ 14.08
Schedule of Restricted Stock Awards Activity	The following table summarizes RSA activity under the Plan: Schedule of Restricted Stock Awards Activity Weighted Average Grant RSA Date Fair Value Unvested balance at October 1, 2022 — $ — Granted 688 $ 226.16 Unvested balance at September 30, 2023 688 $ 226.16 Granted 7,977 $ 14.08 Vested (688 ) $ 226.16 Unvested balance at September 30, 2024 7,977 $ 14.08

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	The tax effects of the temporary differences that gave rise to deferred taxes were as follows: Schedule of Deferred Tax Assets and Liabilities 2024 2023 September 30, 2024 2023 Deferred tax assets: Net operating loss carryforwards $ 26,754,767 $ 27,996,751 Research and development credit carryforwards 3,129,222 3,106,675 Amortization 5,791,883 4,692,227 Share-based compensation 19,357 226 Operating lease liability 36,786 57,319 Accrued expenses and other 26,977 546,612 Section 163(j) disallowed interest expense 761,450 763,172 Gross deferred tax assets 36,520,442 37,162,982 Less: valuation allowance (36,480,967 ) (37,100,582 ) Deferred tax assets 39,475 62,400 Deferred tax liabilities: Property and equipment (4,782 ) (7,954 ) Operating lease right-of-use asset (34,693 ) (54,446 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate Reconciliation	The Company recorded no income tax expense or benefit for the years ended September 30, 2024 and 2023. A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows: Schedule of Effective Income Tax Rate Reconciliation 2024 2023 Years ended September 30, 2024 2023 U.S. federal statutory rate (21.0 ) % (21.0 )% State taxes, net of federal benefit (5.8 ) (7.1 ) Change in valuation allowance (8.3 ) 30.8 Research and development credit (4.6 ) (5.1 ) Permanent differences 2.7 (1.6 ) Foreign tax rate differential 0.1 0.3 State net operating losses — 3.7 Sale of state net operating losses and research and development credits 51.5 — Other (14.6 ) — Effective income tax rate — % — %

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	1 Months Ended
	Dec. 09, 2024	Nov. 30, 2024	Oct. 31, 2024	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents				$ 149,456	$ 2,274,259
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of common stock and warrants	$ 7,700,000
Cash refund from incentive tax receivable		$ 700,000
Subsequent Event [Member] | Alkem Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received		$ 500,000
Net payment after tax with holdings			$ 400,000

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Shares (Details) - shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	1,183,437	91,540
Common Stock Warrants August 2021 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	14,031	16,039
Underwriter Warrants August 2021 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	284	284
Chanticleer Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	6	6
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	2,297	4,591
Series 3 Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	1,566	1,566
Unvested Restricted Stock Units and Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	17,152	288
Common Stock Warrants February 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	33,982	33,982
Underwriter Warrants February 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	1,933	5,523
Common Stock Private Placement Warrants June 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	28,409	28,409
Placement Agent Warrants June 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	852	852
Common Stock Warrants October 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	354,994
Underwriter Warrants October 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	10,664
Placement Agent Warrants June 2024 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	14,142
Common Stock Warrants June 2024 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	703,125

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)			1 Months Ended	12 Months Ended
	Nov. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares
Property, Plant and Equipment [Line Items]
Number of operating segments | Segment				1
Impairment charges of long-lived assets				$ 0	$ 0
Deferred offering costs		$ 15,000		15,000	49,988
Incentive tax receivable current		$ 762,078		762,078	786,574
Other income				$ 4,327,946
Reverse stock split description		1-for-8 reverse stock split
Warrant, shares | shares		1,265,972		1,265,972
Prefunded October 2023 Warrants [Member]
Property, Plant and Equipment [Line Items]
Warrants to purchase common stock | shares		99,687		99,687
Exercise price | $ / shares		$ 0.0008		$ 0.0008
Warrant, shares | shares		187,500		187,500
Series B Warrants [Member]
Property, Plant and Equipment [Line Items]
Warrants to purchase common stock | shares					17
Exercise price | $ / shares					$ 0.25
Minimum [Member]
Property, Plant and Equipment [Line Items]
Research and development credits tax benefits				80%
Research and Development Tax Incentive Program [Member]
Property, Plant and Equipment [Line Items]
Refund Received Related to Revenue from Different Year, Year Revenue Recognized				The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period.
Incentive tax receivable current					$ 800,000
Cash refund	$ 700,000		$ 800,000
Change in foreign exchange rates			$ 100,000
Cash refund expected to be received					$ 800,000

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Payables and Accruals [Abstract]
Compensation and benefits	$ 149,802	$ 2,091,196
Research and development	617,545	913,145
Professional fees	173,319	224,031
Other	1,823	2,550
Accrued expenses and other current liabilities	$ 942,489	$ 3,230,922

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details Narrative) $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($)
Payables and Accruals [Abstract]
Reduced research and development expenses	$ 1
Reduced general and administrative expenses	$ 0.9

Schedule of Lease Expenses (Det

Schedule of Lease Expenses (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating lease expense	$ 90,837	$ 90,837
Variable lease expense	1,472	5,978
Total lease cost	$ 92,309	$ 96,815

Schedule of Operating Lease Lia

Schedule of Operating Lease Liabilities (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating cash flow from operating lease	$ 93,614	$ 79,259

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details)	Sep. 30, 2024 USD ($)
Leases
2025	$ 95,487
2026	48,216
Total undiscounted lease payments	143,703
Less: imputed interest	(12,839)
Total lease liabilities	$ 130,864

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2019
Leases
Lease term		36 months
Increase in operating lease right of use asset	$ 0.2
Increase in operating lease liability	$ 0.2
Weighted-average remaining lease term	1 year 7 months 6 days
Weighted average discount rate	12%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) € in Millions	1 Months Ended			12 Months Ended
	Aug. 31, 2024	Apr. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 EUR (€)	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jan. 31, 2019 USD ($)	Jul. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Payment to acquire in process research and development				$ 12,000	$ 443,250
Discovery Collaboration Agreements [Member] | XOMA [Member]
Loss Contingencies [Line Items]
Milestone payments										$ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees		$ 500,000		$ 0	0
Cellca Agreement [Member]
Loss Contingencies [Line Items]
Description of milestone payments				The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.
Cellca Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments									$ 700,000
The Cellca Agreement [Member]
Loss Contingencies [Line Items]
Milestone payments				$ 600,000
The Cellca Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				600,000
The Cellca Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000
The Cellca Agreement [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees				0	0
Commercial product license fee payment obligation		$ 100,000
The Brink Agreement [Member]
Loss Contingencies [Line Items]
Commercial product license fee payment obligation				100,000
Payment of annual license fee							$ 12,000
The Brink Agreement [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees				12,000	12,000
Development license fee payments				100,000
InvivoGen Agreement [Member]
Loss Contingencies [Line Items]
License fees				0	0
Payment for annual license fee obligation				100,000		€ 0.1
ProteoNic Agreement [Member]
Loss Contingencies [Line Items]
License fees				0	0
ProteoNic Agreement [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees			$ 24,600
SOC Agreement [Member]
Loss Contingencies [Line Items]
Agreements description	the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur to the SOC a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third-party partnership.
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]
Loss Contingencies [Line Items]
Milestone payments								$ 1,000,000
Payment to acquire in process research and development				100,000
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member] | Research and Development Expense [Member]
Loss Contingencies [Line Items]
Milestone payments				0
License fees				$ 0	$ 300,000

Collaboration Revenue (Details

Collaboration Revenue (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2021	Aug. 31, 2020	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collavorative arrangement right and obligation			New Life is also obligated to pay a non-refundable deferred license fee of an additional $1.0 million at the time of the satisfaction of certain milestones, as well as potential additional milestone payments to the Company of up to $19.0 million subject to the achievement of certain development and commercialization milestones. In addition, during the Royalty Term (as defined below), New Life is obligated to pay the Company tiered double-digit royalties ranging from 12% to 30% based on annual net sales of Products in the Exclusive Territory. The “Royalty Term” means, on a Product-by-Product and a country-by-country basis in the Exclusive Territory, the period commencing on the date of the first commercial sale (subject to certain conditions) of such Product in such country in the Exclusive Territory and continuing until New Life ceases commercialization of such Product in the DIPN Field.
Performance obligation			$ 1,000,000
Collaboration revenue			18,626	$ 147,805
License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds for negotiate license agreement		$ 500,000
New Life Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds for negotiate license agreement	$ 500,000
Future milestone payments			1,000,000
Milestone payments			$ 19,000,000
New Life Agreement [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties, percentage			12%
New Life Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties, percentage			30%

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	Sep. 30, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	1,265,972
Common Stock Warrants August 2021 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	14,031
Exercise Price | $ / shares	$ 2,094.40
Expiration Date	Aug. 24, 2026
Underwriter Warrants August 2021 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	284
Exercise Price | $ / shares	$ 2,618
Expiration Date	Aug. 19, 2026
Chanticleer Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	6
Chanticleer Warrants [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 144,144
Expiration Date	Apr. 30, 2027
Chanticleer Warrants [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 224,224
Expiration Date	Dec. 17, 2028
Series C Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	2,297
Exercise Price | $ / shares	$ 7,860.16
Expiration Date	Oct. 16, 2025
Series 3 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	1,566
Exercise Price | $ / shares	$ 717.024
Expiration Date	Aug. 15, 2027
Common Stock Warrants February 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	33,982
Exercise Price | $ / shares	$ 190.08
Expiration Date	Feb. 10, 2028
Underwriter Warrant February 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	1,933
Exercise Price | $ / shares	$ 237.60
Expiration Date	Feb. 08, 2028
Common Stock Private Placement Warrants June 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	28,409
Exercise Price | $ / shares	$ 12.4000
Expiration Date	Jun. 21, 2029
Placement Agent Warrants June 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	852
Exercise Price | $ / shares	$ 118.7824
Expiration Date	Dec. 30, 2026
Common Stock Warrants October 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	354,994
Exercise Price | $ / shares	$ 9.6000
Expiration Date	Oct. 27, 2028
Prefunded Warrants October 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	99,687
Exercise Price | $ / shares	$ 0.0008
Underwriter Warrants October 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	10,664
Exercise Price | $ / shares	$ 16
Expiration Date	Oct. 24, 2028
Placement Agent Warrants June 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	14,142
Exercise Price | $ / shares	$ 14.8800
Expiration Date	Jun. 19, 2029
Common Stock Warrants June 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding | shares	703,125
Exercise Price | $ / shares	$ 12.4000
Expiration Date	Jun. 21, 2029

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Sep. 30, 2024

Jun. 21, 2024

Jun. 19, 2024

May 02, 2024

Oct. 26, 2023

Jun. 30, 2023

Feb. 10, 2023

Aug. 15, 2022

Jun. 30, 2024

Oct. 31, 2023

Jun. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 30, 2023

Accumulated Other Comprehensive Income (Loss) [Line Items]

Offering price for common stock

$ 3,976,382

$ 20,895,958

Financing costs incurred

370,426

Proceeds from sale of common stock

$ 3,896,577

21,006,371

Warrant, shares

1,265,972

1,265,972

Proceeds from warrant exercises

$ 2,983,769

849

Chardan Capital Markets LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

20,795

Purchase of warrants

28,409

28,409

Exercisable price

$ 79.20

$ 79.20

Gross proceeds from private placement

$ 2,300,000

Proceeds from issuance of private placement

$ 1,900,000

Common Stock Warrants October 2023 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 9.6000

$ 9.6000

Warrant exercise price decrease

$ 9.60

Warrant, shares

354,994

354,994

Expiration date

Oct. 27, 2028

Oct. 27, 2028

October Offering [Member] | Underwriters [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Proceeds from sale of common stock

$ 3,900,000

Purchase of warrants

10,664

Exercisable price

$ 16

Warrant expire date

5 years

Public Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Gross proceeds from sale agreement

$ 15,000,000

Proceeds from sale of common stock

$ 13,600,000

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Offering price for common stock

$ 17

$ 10

Number of shares issued

167,987

104,159

Net share settlement of warrants, shares

94,288

64,928

Common Stock [Member] | October Offering [Member] | Underwriters [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of stock, shares

163,281

Exercisable price

$ 0.0001

Common Stock [Member] | Public Offering [Member] | Chardan Capital Markets LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

66,277

Prefunded Warrant [Member] | October Offering [Member] | Underwriters [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

192,187

Sales price, per share

$ 12.7992

Prefunded Warrant [Member] | Public Offering [Member] | Chardan Capital Markets LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

12,636

Sales price, per share

$ 190.0624

Exercisable price

$ 0.02

Common Warrant [Member] | October Offering [Member] | Underwriters [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

710,931

Sales price, per share

$ 12.80

Exercisable price

$ 12.80

Warrant expire date

5 years

Common Warrant [Member] | Public Offering [Member] | Chardan Capital Markets LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

157,818

Sales price, per share

$ 190.08

Exercisable price

$ 190.08

Warrant expire date

5 years

Common Stock Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

94,288

64,928

Warrant, shares

187,500

187,500

Net share settlement of warrants, shares

96,090

126,583

Number of warrant exercised

355,937

17,249

Proceeds from warrant exercises

$ 3,000,000

Number of warrant expired

33

Common Stock Warrants [Member] | Holder [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Forfeited warrants, shares

4,302

Purchase and Registration Rights Agreement [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Offering price for common stock

$ 25,000,000

Number of shares issued

77,771

Sale of stock, percentage

19.99%

Gross proceeds from sale agreement

$ 100,000

Volume weighted average price discount percentage

4%

Sale of stock, shares

4,706

Purchase and Registration Rights Agreement [Member] | Common Stock [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Gross proceeds from sale agreement

$ 25,000,000

Purchase Agreement [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Financing costs incurred

$ 400,000

2022 Sales Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Offering price for common stock

$ 7,800,000

2022 Sales Agreement [Member] | BTIG, LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Offering price for common stock

$ 25,000,000

Gross proceeds from sale agreement

$ 5,700,000

Sale of stock, shares

17,087

Proceeds from sale of common stock

$ 5,500,000

2022 Sales Agreement [Member] | Underwriter Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

5,523

852

Exercisable price

$ 237.60

$ 118.78

Warrant expire date

5 years

2022 Sales Agreement [Member] | Prefunded Warrant [Member] | Chardan Capital Markets LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

7,613

7,613

2022 Sales Agreement [Member] | Common Warrant [Member] | Chardan Capital Markets LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 0.02

$ 118.78

Warrant exercise price decrease

$ 12.40

Inducement Offer Letter Agreements [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 12.80

Warrant exercise price decrease

$ 9.60

Aggregate number of shares issued

353,562

Proceeds from issuance of warrants

$ 2,900,000

Warrant, shares

187,500

187,500

Inducement Offer Letter Agreements [Member] | Placement Agent [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase of warrants

14,142

Exercisable price

$ 14.88

Warrant expire date

5 years

Inducement Offer Letter Agreements [Member] | New Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant, shares

703,125

Inducement Offer Letter Agreements [Member] | Existing Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 12.80

Warrant exercise price decrease

$ 9.60

Warrant, shares

354.994

Inducement Offer Letter Agreements [Member] | Existing Warrant Issued in June 2023 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant, shares

28,409

28,409

Inducement Offer Letter Agreements [Member] | Existing Warrant Issued in June 2023 [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 118.78

$ 118.78

Expiration date

Jun. 21, 2029

Jun. 21, 2029

Inducement Offer Letter Agreements [Member] | Existing Warrant Issued in June 2023 [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 12.40

$ 12.40

Expiration date

Dec. 30, 2026

Dec. 30, 2026

Inducement Offer Letter Agreements [Member] | New Common Stock Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercisable price

$ 12.40

Warrant expire date

5 years

Schedule of Share-based Compens

Schedule of Share-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation	$ 231,190	$ 248,626
Restricted Stock Units (RSUs) [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation	109,356	121,265
Restricted Stock Units (RSUs) [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation	$ 121,834	$ 127,361

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares		12 Months Ended
	Jan. 01, 2024	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested beginning balance		288	266
Unvested weighted average grant fair value, beginning balance		$ 174.26	$ 1,507.76
Restricted stock unit, granted	9,175	9,175	976
Weighted average grant fair value, granted		$ 14.08	$ 171.77
Restricted stock unit, vested		(288)	(266)
Weighted average grant fair value, vested		$ 174.26	$ 1,507.76
Restricted stock unit, forfeited			(688)
Weighted average grant fair value, forfeited			$ 170.72
Unvested ending balance		9,175	288
Unvested weighted average grant fair value, ending balance		$ 14.08	$ 174.26

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock Awards (RSA) [Member] - $ / shares		12 Months Ended
	Jan. 01, 2024	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested beginning balance		688
Unvested weighted average grant fair value, beginning balance		$ 226.16
Restricted stock unit, granted	7,977	7,977	688
Weighted average grant fair value, granted		$ 14.08	$ 226.16
Restricted stock awards, vested		(688)
Weighted average grant fair value, vested		$ 226.16
Unvested ending balance		7,977	688
Unvested weighted average grant fair value, ending balance		$ 14.08	$ 226.16

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($)			1 Months Ended				12 Months Ended
	Jan. 01, 2025	Jan. 01, 2024	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Sep. 30, 2024	Sep. 30, 2023
Forecast [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting percentage	100%
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted		9,175					9,175	976
Restricted stock units and vesting rights, description				In December of 2022, 976 RSUs were granted, 100% of which vested on January 1, 2024.	In December of 2021, 259 RSUs were granted, 100% of which vested on January 1, 2023.	In March of 2021, an additional 19 RSUs were granted, 50% of which vested on March 25, 2022 and the remaining 50% vested on March 25, 2023.
Number of shares granted				976	259	19
Restricted stock, shares issued			688
Stock compensation modification, incremental expense			$ 38,837
Unrecognized compensation expense							$ 32,314
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average period							3 months
Restricted Stock Awards (RSA) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted		7,977					7,977	688
Unrecognized compensation expense							$ 28,080
Restricted Stock Awards (RSA) [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average period							3 months
2020 Omnibus Equity Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for issuance		17,157					5

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 26,754,767	$ 27,996,751
Research and development credit carryforwards	3,129,222	3,106,675
Amortization	5,791,883	4,692,227
Share-based compensation	19,357	226
Operating lease liability	36,786	57,319
Accrued expenses and other	26,977	546,612
Section 163(j) disallowed interest expense	761,450	763,172
Gross deferred tax assets	36,520,442	37,162,982
Less: valuation allowance	(36,480,967)	(37,100,582)
Deferred tax assets	39,475	62,400
Property and equipment	(4,782)	(7,954)
Operating lease right-of-use asset	(34,693)	(54,446)
Net deferred tax assets

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	(21.00%)	(21.00%)
State taxes, net of federal benefit	(5.80%)	(7.10%)
Change in valuation allowance	(8.30%)	30.80%
Research and development credit	(4.60%)	(5.10%)
Permanent differences	2.70%	(1.60%)
Foreign tax rate differential	0.10%	0.30%
State net operating losses		3.70%
Sale of state net operating losses and research and development credits	51.50%
Other	(14.60%)
Effective income tax rate

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Aug. 31, 2022
Effective Income Tax Rate Reconciliation [Line Items]
Tax credit carryforwards	$ 3,129,222	$ 3,106,675
Increase (decrease) in valuation allowance	(600,000)	5,800,000
Other income	4,327,946
Excise tax			1%
Minimum [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Corporate alternative tax			15%
New Jersey Division of Taxation [Member]
Effective Income Tax Rate Reconciliation [Line Items]
State of net operating losses	49,400,000	$ 0
Sale of unused research and development tax credits	300,000
Other income	4,400,000
Domestic Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Net operating losses	107,500,000
Tax credit carryforwards	2,600,000
State and Local Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Net operating losses	24,400,000
Tax credit carryforwards	500,000
Foreign Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Net operating losses	$ 16,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions			1 Months Ended
	Dec. 09, 2024	Nov. 06, 2024	Dec. 09, 2024	Dec. 10, 2024	Oct. 31, 2024	Oct. 08, 2024
Subsequent Event [Line Items]
Proceeds from offering			$ 7.7
Alkem Agreement [Member]
Subsequent Event [Line Items]
[custom:UpfrontPaymentReceivable-0]					$ 0.5	$ 1
Milestone payment receivable						$ 1
Net payment after tax withholdings					$ 0.4
Underwriting Agreement [Member] | Chardan Capital Markets LLC [Member]
Subsequent Event [Line Items]
Number of shares sold		155,000
Proceeds from offering		$ 4.2
Underwriting Agreement [Member] | Chardan Capital Markets LLC [Member] | Prefunded Warrant [Member]
Subsequent Event [Line Items]
Warrants to purchase common stock		956,111
Offering price per share		$ 4.4999
Underwriting Agreement [Member] | Chardan Capital Markets LLC [Member] | Warrant [Member]
Subsequent Event [Line Items]
Warrants to purchase common stock		2,222,222
Offering price per share		$ 4.50
Definitive Agreement [Member]
Subsequent Event [Line Items]
Proceeds from offering	$ 3.5
Definitive Agreement [Member] | Registered Direct Offering [Member]
Subsequent Event [Line Items]
Offering price per share	$ 2.23		$ 2.23
Definitive Agreement [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Offering price per share	$ 2.23		$ 2.23
Definitive Agreement [Member] | Warrant [Member] | Registered Direct Offering [Member]
Subsequent Event [Line Items]
Warrants to purchase common stock	1,085,325		1,085,325
Exercise price	$ 2.10		$ 2.10
Warrants term	5 years		5 years
Definitive Agreement [Member] | Warrant [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Warrants to purchase common stock	673,000		673,000
Exercise price				$ 2.10
Definitive Agreement [Member] | Common Stock [Member] | Registered Direct Offering [Member]
Subsequent Event [Line Items]
Number of shares sold	1,085,325
Definitive Agreement [Member] | Common Stock [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Number of shares sold	673,000